USA flag logo/image

An Official Website of the United States Government

TcdB Based Protein Delivery of iPSC Reprogramming Factors

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43GM093530
Solicitation Year:
2011
Solicitation Topic Code:
NIGMS
Solicitation Number:
PA10-050
Small Business Information
Synaptic Research, Llc
1448 South Rolling Road Baltimore, MD 21227-3898
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: TcdB Based Protein Delivery of iPSC Reprogramming Factors
Agency: HHS
Contract: 1R43GM093530-01A1
Award Amount: $324,516.00
 

Abstract:

DESCRIPTION (provided by applicant): Induced pluripotent stem cells (iPSC) have tremendous potential for regenerative medicine in future. However, there are obstacles to overcome before the iPSC can be used therapeutically. One major hurdle is the tool used to generate iPSC from adult somatic cells. We believe that the delivery of reprogramming proteins directly rather than the genes that encode these proteins is the safest means for generating iPSC. We propose to engineer Clostridium difficile toxin TcdB as a cytosolic delivery vehicle for embryonic transactivators that can reprogram adult somatic cells to induced pluripotent stem cells (iPSC) and/or tissue specific cells. C. difficile toxin TcdB, exhibits multiple modular domains that provide all the mechanisms that allow the toxin efficiently deliver its N-terminal enzymatic domain (GT domain) to cytosol. We will engineer TcdB as a universal protein delivery vehicle by replaceing the enzymatic domain with a protein cargo to provide therapeutic benefits.We will initially append a chimeric transacivator to the N-terminus of the toxin or replace the GT domain with the chimeric transactivator. Using a high-throughput reporter cell line system, we will first examine how effectively the engineered recombinantprotein can deliver a biologically active cargo. We will then test if the engineered TcdB can deliver biologically active reprogramming factors (Oct4 and Sox2) to another reporter cell line and assess their ability to differentiate mouse embryonic stem cells with the help of our collaborators. Finally, we will use the TcdB delivery vehicle to generate of iPSC from mouse embryonic fibroblasts after we demonstrate that we can deliver those reprogramming factors efficiently to the well-characterized reportercells. Other methods of delivering proteins, such as the TAT protein transduction domain, will be tested in parallel to compare the efficiency of our novel system to established techniques. We believe this TcdB-based protein delivery vehicle will be a valuable tool for generating iPSC for research purposes, drug development, and toxicology studies. We also anticipate the development of TcdB-based biologics for regenerative medicine. PUBLIC HEALTH RELEVANCE: This project will investigate the use of anew protein delivery vehicle to introduce reprogramming factors to adult skin cells in order to convert them to induced pluripotent stem cells (iPSC). This approach relies on proteins rather than genes to create iPSC, which avoids the potential dangers ofgenetic modification. These iPSC have enormous potential to replace embryonic stem cells for regenerative medicine.

Principal Investigator:

Yung N. Chang
301-987-0480
yung.chang@synapticresearch.com

Business Contact:

Yung N. Chang
443-543-5890
yung.chang@synapticresearch.com
Small Business Information at Submission:

SYNAPTIC RESEARCH, LLC
1448 S Rolling Road BALTIMORE, MD 21227-

EIN/Tax ID: 120548722
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No